SCHEMBL12599532

SCHEMBL12599532

CC1(C)CCc2c(O)cc(O)c(C(=O)/C=C/c3ccccc3)c2O1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NFKB1 P19838 7/20 0.50
▸ NFKB2 Q00653 7/20 0.50
▸ RELA Q04206 7/20 0.50
▸ SLC5A1 P13866 1/20 0.50
▸ SLC5A2 P31639 1/20 0.50
▸ CYP19A1 P11511 1/20 0.48
▸ CYP2C9 P11712 1/20 0.48
▸ MAOA P21397 1/20 0.48
▸ MAOB P27338 1/20 0.48
▸ CYP2C19 P33261 1/20 0.48
▸ MAPT P10636 4/20 0.46
▸ KMT2A Q03164 3/20 0.46
▸ KCNA3 P22001 2/20 0.46
▸ NPSR1 Q6W5P4 2/20 0.46
▸ MEN1 O00255 2/20 0.46
▸ TP53 P04637 1/20 0.45
▸ CYP3A4 P08684 1/20 0.45
▸ ATM Q13315 1/20 0.45
▸ HSD17B10 Q99714 1/20 0.45
▸ ABCG2 Q9UNQ0 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23728437 0.83 NFKB1 (0.47) NFKB1NFKB2RELASLC5A1SLC5A2
SCHEMBL23728227 0.83 NFKB1 (0.47) NFKB1NFKB2RELASLC5A1SLC5A2
SCHEMBL25437405 0.77 NFKB1 (0.52) NFKB1NFKB2RELASLC5A1SLC5A2
SCHEMBL12599531 0.76 HPGD (0.42) NFKB1NFKB2RELAKMT2AMEN1
SCHEMBL25301405 0.75 NFKB1 (0.50) NFKB1NFKB2RELASLC5A1SLC5A2
SCHEMBL17150170 0.74 NFKB1 (0.66) NFKB1NFKB2RELACYP2C9CYP2C19
SCHEMBL12599524 0.74 MAPT (0.58) NFKB1NFKB2RELASLC5A1SLC5A2
SCHEMBL15620334 0.74 NFKB1 (0.48) NFKB1NFKB2RELACYP19A1CYP2C9
SCHEMBL30335008 0.74 MAPT (0.58) NFKB1NFKB2RELASLC5A1SLC5A2
SCHEMBL25301601 0.73 MAPT (0.52) NFKB1NFKB2RELAMAOBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8586768-B2 Design, synthesis and functional characterization of rottlerin analogs IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) 2013-11-19 — — US disclosed
US-20110112182-A1 DESIGN, SYNTHESIS AND FUNCTIONAL CHARACTERIZATION OF ROTTLERIN ANALOGS IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) 2011-05-12 — — US disclosed
US-20110112182-A1 DESIGN, SYNTHESIS AND FUNCTIONAL CHARACTERIZATION OF ROTTLERIN ANALOGS IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) 2011-05-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110112182-A1 DESIGN, SYNTHESIS AND FUNCTIONAL CHARACTERIZATION OF ROTTLERIN ANALOGS PRKCH, PRKCB, PRKCA NFKB1 1069/4885NFKB2 1366/4885RELA 2357/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback